Dogwood upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Dogwood (DWTX) to Buy from Neutral with a $10 price target The most important catalyst for Dogwood in 2025 is the upcoming interim results from the Phase 2b study of halneuron, the company’s lead product, for the management of chemotherapy-induced neuropathic pain, the analyst tells investors in a research note. The firm cites its positive outlook on the upcoming interim results and its assessment of halneuron’s market opportunity for the upgrade.